Aurobindo acquires Mylan’s clorazepate dipotassium tablets

Aurobindo has acquired clorazepate dipotassium tablets from Mylan, a Viatris company. The drug was acquired in dosage strengths of 3.75 mg, 7.5 mg and 15 mg.

Aurobindo began to market, distribute, and sell these products as of Jan. 1.

Clorazepate cipotassium tablets are indicated for the management of anxiety disorders, for short-term relief of the symptoms of anxiety, and as an adjunct therapy in the management of partial seizures.